Graviton BioScience Corporation

Graviton BioScience Announces FDA Fast Track Designation for GV101 for the Treatment of Friedreich's Ataxia

Fast Track Designation recognizes the serious unmet medical need in Friedreich's ataxia and is intended to facilitate the development and expedite…